Advances of induced pluripotent stem cells in Alzheimer’s disease: A bibliometric analysis
Abstract
Objective: Alzheimer’s disease (AD), as a progressive neurological disorder that primarily affects memory, thinking skills, and behavior, is the most common cause of dementia, but there is no cure for AD. Induced pluripotent stem cells (iPSCs) therapy, as an emerging therapeutic strategy, brings new hope for the treatment of these diseases. This study aims to explore the research hotspots, development trends and future directions of iPSCs therapy in AD. Methods: By quantitatively analyzing the relevant literature, we screened all Science Citation Index Expanded (SCI-EXPANDED) and Social Sciences Citation Index (SSCI) related literature about iPSCs and AD from 1900-2024 from Web of Science, and analyzed the research trends in this field by using VOSviewer and bibliometric analysis online platforms etc. Results: A total of 718 related literature were screened from the Web of Science Core Collection database according to the search strategy. Bibliometric analysis revealed that the number of publications on iPSCs and AD has shown a growing trend, with an annual average of more than 90 publications over the past five years, which is a hot spot in recent years. Notably, Li-Huei Tsai is the most productive and influential author in the field. Harvard Medical School ranks as the institution with the largest number of publications, while Stem Cell Research stands out as the journal with the most publications on this topic. Furthermore, the United States makes the largest contribution to this field. Conclusions: iPSCs therapy has been become a hot spot in AD research, and the main contributor is from the United States.
Publisher
Idragon publisher
Reference24 articles.
1. Armijo, E., Gonzalez, C., Shahnawaz, M., Flores, A., Davis, B., & Soto, C. (2017). Increased susceptibility to Aβ toxicity in neuronal cultures derived from familial Alzheimer's disease (PSEN1-A246E) induced pluripotent stem cells. Neuroscience Letters, 639, 74-81. https://doi.org/10.1016/j.neulet.2016.12.060 2. Atri, A. (2019). Current and Future Treatments in Alzheimer's Disease. Semin Neurol, 39(2), 227-240. https://doi.org/10.1055/s-0039-1678581 3. Cha, M. Y., Kwon, Y. W., Ahn, H. S., Jeong, H., Lee, Y. Y., Moon, M., Baik, S. H., Kim, D. K., Song, H., Yi, E. C., Hwang, D., Kim, H. S., & Mook-Jung, I. (2017). Protein-Induced Pluripotent Stem Cells Ameliorate and Reduce Aβ Deposition of Alzheimer's Disease. Stem Cells Translational Medicine, 6(1), 293-305. https://doi.org/10.5966/sctm.2016-0081 4. Du, Y. H., Yang, R. Y., Wang, Q., Wang, L. Y., Liang, L. C., Zhu, L., Sun, Y., & Cai, M. (2021). Bibliometric Analysis Study on the Mechanisms of Brain Energy Metabolism Disorders in Alzheimer's Disease From 2000 to 2020. Frontiers in Neurology, 12, 13, Article 670220. https://doi.org/10.3389/fneur.2021.670220 5. Giunti, E., Collu, R., Daley, S., Querfurth, H., Morin, P., Killick, R., Melamed, R. D., & Xia, W. M. (2023). Reduction of Phosphorylated Tau in Alzheimer's Disease Induced Pluripotent Stem Cell-Derived Neuro-Spheroids by Rho-Associated Coiled-Coil Kinase Inhibitor Fasudil. Journal of Alzheimers Disease, 96(4), 1695-1709. https://doi.org/10.3233/jad-230551
|
|